vs
Amphastar Pharmaceuticals, Inc.（AMPH）とAPOGEE ENTERPRISES, INC.（APOG）の財務データ比較。上の社名をクリックして会社を切り替えられます
APOGEE ENTERPRISES, INC.の直近四半期売上が大きい（$351.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.9倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 4.7%、差は8.6%）。APOGEE ENTERPRISES, INC.の前年同期比売上増加率が高い（1.6% vs -1.8%）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 2.9%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Apogee Enterprisesはアメリカのオーディオ機器メーカーです。オーディオインターフェース、AD/DAコンバーター、USB・iOS対応マイクの製造を主軸に、オーディオ制作向けソフトウェアの開発も手がけており、プロの録音や音楽制作分野で広く利用されています。
AMPH vs APOG — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $351.4M |
| 純利益 | $24.4M | $16.6M |
| 粗利率 | 46.8% | 22.4% |
| 営業利益率 | 19.4% | 7.3% |
| 純利益率 | 13.3% | 4.7% |
| 売上前年比 | -1.8% | 1.6% |
| 純利益前年比 | -35.7% | 568.8% |
| EPS（希薄化後） | $0.51 | $0.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $351.4M | ||
| Q4 25 | $183.1M | $348.6M | ||
| Q3 25 | $191.8M | $358.2M | ||
| Q2 25 | $174.4M | $346.6M | ||
| Q1 25 | $170.5M | $345.7M | ||
| Q4 24 | $186.5M | $341.3M | ||
| Q3 24 | $191.2M | $342.4M | ||
| Q2 24 | $182.4M | $331.5M |
| Q1 26 | — | $16.6M | ||
| Q4 25 | $24.4M | $16.5M | ||
| Q3 25 | $17.4M | $23.6M | ||
| Q2 25 | $31.0M | $-2.7M | ||
| Q1 25 | $25.3M | $2.5M | ||
| Q4 24 | $38.0M | $21.0M | ||
| Q3 24 | $40.4M | $30.6M | ||
| Q2 24 | $37.9M | $31.0M |
| Q1 26 | — | 22.4% | ||
| Q4 25 | 46.8% | 23.8% | ||
| Q3 25 | 51.4% | 23.1% | ||
| Q2 25 | 49.6% | 21.7% | ||
| Q1 25 | 50.0% | 21.6% | ||
| Q4 24 | 46.5% | 26.1% | ||
| Q3 24 | 53.3% | 28.4% | ||
| Q2 24 | 52.2% | 29.8% |
| Q1 26 | — | 7.3% | ||
| Q4 25 | 19.4% | 7.1% | ||
| Q3 25 | 13.2% | 7.5% | ||
| Q2 25 | 24.2% | 2.0% | ||
| Q1 25 | 21.9% | 1.8% | ||
| Q4 24 | 24.2% | 8.4% | ||
| Q3 24 | 29.8% | 12.3% | ||
| Q2 24 | 30.3% | 12.5% |
| Q1 26 | — | 4.7% | ||
| Q4 25 | 13.3% | 4.7% | ||
| Q3 25 | 9.0% | 6.6% | ||
| Q2 25 | 17.8% | -0.8% | ||
| Q1 25 | 14.8% | 0.7% | ||
| Q4 24 | 20.4% | 6.1% | ||
| Q3 24 | 21.1% | 8.9% | ||
| Q2 24 | 20.8% | 9.4% |
| Q1 26 | — | $0.78 | ||
| Q4 25 | $0.51 | $0.77 | ||
| Q3 25 | $0.37 | $1.10 | ||
| Q2 25 | $0.64 | $-0.13 | ||
| Q1 25 | $0.51 | $0.12 | ||
| Q4 24 | $0.74 | $0.96 | ||
| Q3 24 | $0.78 | $1.40 | ||
| Q2 24 | $0.73 | $1.41 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $39.5M |
| 総負債低いほど良い | $608.7M | $232.3M |
| 株主資本純資産 | $788.8M | $511.8M |
| 総資産 | $1.6B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.45× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $39.5M | ||
| Q4 25 | $282.8M | $41.3M | ||
| Q3 25 | $276.2M | $39.5M | ||
| Q2 25 | $231.8M | $32.8M | ||
| Q1 25 | $236.9M | $41.4M | ||
| Q4 24 | $221.6M | $43.9M | ||
| Q3 24 | $250.5M | $51.0M | ||
| Q2 24 | $217.8M | $30.4M |
| Q1 26 | — | $232.3M | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | $285.0M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $511.8M | ||
| Q4 25 | $788.8M | $512.3M | ||
| Q3 25 | $776.7M | $500.2M | ||
| Q2 25 | $757.5M | $481.8M | ||
| Q1 25 | $751.3M | $487.9M | ||
| Q4 24 | $732.3M | $522.1M | ||
| Q3 24 | $727.7M | $506.4M | ||
| Q2 24 | $713.3M | $480.0M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $917.1M | ||
| Q2 24 | $1.5B | $889.0M |
| Q1 26 | — | 0.45× | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 0.58× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $122.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | — |
| FCFマージンFCF / 売上 | 13.4% | — |
| 設備投資強度設備投資 / 売上 | 4.5% | 7.8% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 7.37× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $122.5M | ||
| Q4 25 | $32.9M | $29.3M | ||
| Q3 25 | $52.6M | $57.1M | ||
| Q2 25 | $35.6M | $-19.8M | ||
| Q1 25 | $35.1M | $30.0M | ||
| Q4 24 | $29.0M | $31.0M | ||
| Q3 24 | $60.0M | $58.7M | ||
| Q2 24 | $69.1M | $5.5M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $22.9M | ||
| Q3 25 | $47.2M | $52.4M | ||
| Q2 25 | $25.0M | $-26.9M | ||
| Q1 25 | $24.4M | $19.1M | ||
| Q4 24 | $16.6M | $22.0M | ||
| Q3 24 | $46.2M | $50.2M | ||
| Q2 24 | $63.1M | $-1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 6.6% | ||
| Q3 25 | 24.6% | 14.6% | ||
| Q2 25 | 14.3% | -7.8% | ||
| Q1 25 | 14.3% | 5.5% | ||
| Q4 24 | 8.9% | 6.4% | ||
| Q3 24 | 24.1% | 14.7% | ||
| Q2 24 | 34.6% | -0.5% |
| Q1 26 | — | 7.8% | ||
| Q4 25 | 4.5% | 1.9% | ||
| Q3 25 | 2.8% | 1.3% | ||
| Q2 25 | 6.1% | 2.1% | ||
| Q1 25 | 6.3% | 3.2% | ||
| Q4 24 | 6.7% | 2.6% | ||
| Q3 24 | 7.2% | 2.5% | ||
| Q2 24 | 3.3% | 2.2% |
| Q1 26 | — | 7.37× | ||
| Q4 25 | 1.35× | 1.77× | ||
| Q3 25 | 3.03× | 2.41× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 12.08× | ||
| Q4 24 | 0.76× | 1.48× | ||
| Q3 24 | 1.48× | 1.92× | ||
| Q2 24 | 1.82× | 0.18× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
